Compare Ginkgo Bioworks Holdings Inc (DNA) vs GameStop Corp. (GME) Price & Performance

Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.

The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.

GME trades at $18.605, down 0.98% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.30 beating expectations of $0.16. Revenue for 2025 was $3.82B, with net income of $131.3M and a profit margin of 3.43%. Recent news highlights a potential shift from a $56B eBay takeover bid to a partnership, as reported by Bloomberg on August 10, 2026.

The outlook is mixed: strong profitability improvements and debt reduction support upside, but analyst consensus is cautious with only 16.67% buy ratings. Key risks include execution of strategic partnerships, competitive pressures in retail, and shareholder dilution from recent debt-for-stock swaps. The stock's valuation appears reasonable with a P/E of 14.04, but sentiment remains divided.